Serum Uric Acid and Cardiovascular Disease Risk

Letters4 April 2000Serum Uric Acid and Cardiovascular Disease RiskBruce F. Culleton, MD, Martin G. Larson, ScD, and Daniel Levy, MDBruce F. Culleton, MDUniversity of Calgary; Calgary, Alberta, Canada T2N 2T9 (Culleton)National Heart, Lung, and Blood Institute; Framingham Heart Study; Framingham, MA 01702 (Larson)National Heart, Lung, and Blood Institute; Framingham Heart Study; Framingham, MA 01702 (Levy)Search for more papers by this author, Martin G. Larson, ScDUniversity of Calgary; Calgary, Alberta, Canada T2N 2T9 (Culleton)National Heart, Lung, and Blood Institute; Framingham Heart Study; Framingham, MA 01702 (Larson)National Heart, Lung, and Blood Institute; Framingham Heart Study; Framingham, MA 01702 (Levy)Search for more papers by this author, and Daniel Levy, MDUniversity of Calgary; Calgary, Alberta, Canada T2N 2T9 (Culleton)National Heart, Lung, and Blood Institute; Framingham Heart Study; Framingham, MA 01702 (Larson)National Heart, Lung, and Blood Institute; Framingham Heart Study; Framingham, MA 01702 (Levy)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-7-200004040-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:First, we thank Drs. Vaccarino and Krumholz for their flattering editorial about our article, particularly their praise of the contributions of the Framingham Heart Study to cardiovascular disease risk assessment (1). We are also pleased to respond to Dr. Alderman's comments.We believe that critical differences in the designs of the studies may explain their disparate results. First, our report used data collected from a community-based sample. In contrast, Alderman and colleagues' study (2) was clinic-based and included only hypertensive patients. Second, residual confounding may also account for some of the differences. The NHANES I epidemiologic follow-up study ...References1. Vaccarino V, Krumholz HM. Risk factors for cardiovascular disease: one down, many more to evaluate [Editorial]. Ann Intern Med. 1999;131:62-3. LinkGoogle Scholar2. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999;34:144-50. CrossrefMedlineGoogle Scholar3. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I epidemiologic follow-up study. Am J Epidemiol. 1995;141:637-44. CrossrefMedlineGoogle Scholar4. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol. 1989;42:257-67. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Calgary; Calgary, Alberta, Canada T2N 2T9 (Culleton)National Heart, Lung, and Blood Institute; Framingham Heart Study; Framingham, MA 01702 (Larson)National Heart, Lung, and Blood Institute; Framingham Heart Study; Framingham, MA 01702 (Levy) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRisk Factors for Cardiovascular Disease: One Down, Many More To Evaluate Viola Vaccarino and Harlan M. Krumholz Metrics 4 April 2000Volume 132, Issue 7Page: 592KeywordsCardiovascular disease riskCardiovascular diseasesDiureticsHeartHypertensionLongitudinal studiesObservational studiesResearch designType 2 diabetesUric acid ePublished: 15 August 2000 Issue Published: 4 April 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...